Epstein Secrets

ng "big game" • Short time & limited capital to profit/liquidity • I have hands-on experience doing this successfully • Competitive fees - 2%/20% Target >25% ROI for the portfolio. 3x return in 5 years, 5x return in 7 years DACART CAPITAL LLC EFTA_R1_01138845 EFTA02295571 Return on Investment X

P, OM* • Growth factors, ctt(Npese Lumen Intim° [D.L-S P,FIT CAPITAL LLC EFTA_R1_01138815 EFTA02295541 Mechanism of Neointimal Thickening Medial SMC proliferation Lumen .Er-iclothelial cells Growth factors, ctfdlitits O° OO DACART CAPITAL Lac Intim° Adventitin EFTA_R1_01138816 EFTA02295542

ng "big game" • Short time & limited capital to profit/liquidity • I have hands-on experience doing this successfully • Competitive fees — 2%/20% Target >25% ROI for the portfolio. 3x return in 5 years, 5x return in 7 years DACARI CAPI I AL LL, EFTA00506150 Return on Investment Xenogen Jan-98

IMIP Lumen Intima Adventitia Fibroblasts, fat cells, interstitial matrix DACART CAPITAL LLC7 EFTA00506120 Mechanism of Neointimal Thickening Medial SMC proliferation () 0 0 0 0 0 0 0 Endothelial cells Growth factors, cit6b%-- oc) 00 Lumen Intima Fibroblasts, fat cells, interstitial IMP

ng "big game" • Short time & limited capital to profit/liquidity • I have hands-on experience doing this successfully • Competitive fees — 2%/20% Target >25% ROI for the portfolio. 3x return in 5 years, 5x return in 7 years DACARI CAPI I AL LL, EFTA00506197 Advisory Board Thomas Shenk, • Dr. S

110 411•1. 411Mir Fibroblasts, fat cells, interstitial matrix Adventitia DACART CAPITAL LLC7 EFTA00506173 Mechanism of Neointimal Thickening Medial SMC proliferation Adventitia Fibroblasts, fat cells, intersti '- ' DACART CAP' JAL LLC: EFTA00506174 SMC migration and neointimal lesion developmen